ArticleBritish journal of cancer2003
Zoledronic acid induces antiproliferative and apoptotic effects in human pancreatic cancer cells in vitro.
Article in British journal of cancer, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00892242 (Perioperative Treatment With Zoledronic Acid in Patients With Resectable Pancreas Cancer), which is not on this map. Cited by 55 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Perioperative Treatment With Zoledronic Acid in Patients With Resectable Pancreas Cancer
Who cites it
55 citing papers in PubMed, 155 citations in OpenAlex.
- The Cellular and Mitochondrial Consequences of Mevalonate Pathway Inhibition by Nitrogen-Containing Bisphosphonates: A Narrative Review.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Cytotoxic and apoptotic effects of zoledronic acid on D-17 canine osteosarcoma cell line.Iranian journal of veterinary research · 2024Article
- Investigating the Underlying Molecular Mechanisms of Yunke on Bone Metastases from Prostate Cancer.Biologics : targets & therapy · 2024Article
- Geranylgeranyl diphosphate synthase: Role in human health, disease and potential therapeutic target.Clinical and translational medicine · 2023Review
- The Osteoclast Traces the Route to Bone Tumors and Metastases.Frontiers in cell and developmental biology · 2022Review
- Zoledronic acid-loaded lipidic nanoparticles enhance apoptosis and attenuate invasiveness by inhibiting epithelial to mesenchymal transition (EMT) in HepGNaunyn-Schmiedeberg's archives of pharmacology · 2021Article
- Bisphosphonate Use Does Not Impact Survival in Patients with Pancreatic Cancer: A Propensity Score Matching Analysis.Gut and liver · 2021Article
- The effects of bisphosphonate and radiation therapy in bone-metastatic lung adenocarcinoma: the impact of KRAS mutation.Translational lung cancer research · 2021Article
- Various pathways of zoledronic acid against osteoclasts and bone cancer metastasis: a brief review.BMC cancer · 2020Review
- Article
- Next Generation Lipophilic Bisphosphonate Shows Antitumor Effect in Colorectal Cancer In Vitro and In Vivo.Pathology oncology research : POR · 2020Article
- Zoledronic acid inhibits the growth of cancer stem cell derived from cervical cancer cell by attenuating their stemness phenotype and inducing apoptosis and cell cycle arrest through the Erk1/2 and Akt pathways.Journal of experimental & clinical cancer research : CR · 2019Article
- Low-dose zoledronate for the treatment of bone metastasis secondary to prostate cancer.Cancer cell international · 2019Article
- Zoledronic acid exhibits radio-sensitizing activity in human pancreatic cancer cells via inactivation of STAT3/NF-κB signaling.OncoTargets and therapy · 2019Article
- Preclinical evaluation of an innovative anti-TAM approach based on zoledronate-loaded erythrocytes.Drug delivery and translational research · 2018Article
- The combination of everolimus and zoledronic acid increase the efficacy of gemcitabine in a mouse model of pancreatic adenocarcinoma.Oncotarget · 2018Article
- Zoledronate inhibits fibroblasts' proliferation and activation via targeting TGF-β signaling pathway.Drug design, development and therapy · 2018Article
- Zoledronic acid impairs stromal reactivity by inhibiting M2-macrophages polarization and prostate cancer-associated fibroblasts.Oncotarget · 2017Article
- KRAS-mutation status dependent effect of zoledronic acid in human non-small cell cancer preclinical models.Oncotarget · 2016Article
- The Role of Common Pharmaceutical Agents on the Prevention and Treatment of Pancreatic Cancer.Gut and liver · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bisphosphonates (BPs) are an emerging class of drugs mostly used in the palliative care of cancer patients. We investigated the in vitro activity of the most potent antiresorptive BP, zoledronic acid (ZOL), on the growth and survival of three human pancreatic cancer (PC) cell lines (BxPC-3, CFPAC-1 and PANC-1). Pancreatic cancer frequently has a dysregulated p21(ras) pathway and therefore appears to be a suitable target for BPs that interfere with the prenylation of small GTP-binding proteins such as p21(ras). We found that ZOL induces growth inhibition (IC(50):10-50 micro M) and apoptotic death of PC cells. The proapoptotic effect was correlated to cleavage/activation of caspase-9 and poly(ADP)-ribose polymerase, but not of caspase-3. Moreover, we studied the p21(ras) signalling in cells exposed to ZOL and detected a reduction of p21(ras) and Raf-1 content and functional downregulation of the terminal enzyme ERK/MAPkinase and of the pKB/Akt survival pathway. Finally, we observed that ZOL induces significant cytoskeletal rearrangements. In conclusion, we demonstrated that ZOL induces growth inhibition and apoptosis on PC cells and interferes with growth and survival pathways downstream to p21(ras). These findings might be relevant for expanding application of BPs in cancer treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.